| Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia |
Ongoing |
Jardiance |
4 |
1245/149 |
Armed Force Hospital (Al-Hada), King Fahad Medical City (Riyadh) |
| A single-arm interventional Phase IV, post-authorisationstudy evaluating the safety of pediatric patients withtransfusional hemosiderosis treated with deferasiroxcrushed film coated tablets |
Ongoing |
Deferasirox |
4 |
CICL670F24 |
King Abdulaziz Medical City NG (Jeddah) |
| Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial |
Ongoing |
Ketamine |
3 |
2191187 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| AURIGA / An observationAl stUdy pRogram toInvestiGate the effectiveness of intravitreal Aflibercept indiabetic macular edema and/or macular edema secondary toretinal vein occlusion in a real world setting. |
Ongoing |
Aflibercept |
4 |
19157 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Khaled Eye Specialist Hospital (Riyadh) |
| "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" |
Ongoing |
Ertugliflozin |
3 |
MK-8835-059-00 |
King Salman Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh) |
| Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer |
Ongoing |
CARVEDILOL |
3 |
S1501 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation |
Ongoing |
Acalabrutinib |
3 |
D8221C00001 |
King Fahad Specialist Hospital (Dammam) |
| "A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)" |
Ongoing |
Capivasertib |
3 |
D3614C00001 |
King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh) |
| AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY |
Terminated |
Risdiplam |
2 |
BN40703 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
Ongoing |
DOCETAXEL, Paclitaxel, TAMOXIFEN and Letrozole |
3 |
S1007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
